

CENTRAL INTELLIGENCE AGENCY

# INFORMATION REPORT

REPORT NO.

CD NO.

COUNTRY East Germany

DATE DISTR. 22 June 1953

SUBJECT Dextran Production at VEB Serum-Werk Dessau

NO. OF PAGES 1

PLACE  
ACQUIRED

NO. OF ENCLS.  
LISTED BELOW

DATE OF  
INFO.

SUPPLEMENT TO  
REPORT NO.

THIS DOCUMENT CONTAINS INFORMATION AFFECTING THE NATIONAL DEFENSE  
OF THE UNITED STATES. WITHIN THE MEANING OF TITLE 18, SECTIONS 793  
AND 794, OF THE U. S. CODE, AS AMENDED. ITS TRANSMISSION OR REVEL-  
ATION OF ITS CONTENTS TO OR RECEIPT BY AN UNAUTHORIZED PERSON  
IS PROHIBITED BY LAW. THE REPRODUCTION OF THIS FORM IS PROHIBITED.

THIS IS UNEVALUATED INFORMATION

1. VEB Serum-Werk, Dessau is engaged at present in the study of methods for the production of dextran and dextran-sulfate. This work was suggested by biologist Jaydrusch, but bacteriologist Dr. med. Koepfel 1/ has claimed credit for the idea. Between 60,000 and 90,000 DM East have been allocated to the plant for the development of dextran, a money grant quite apart from the total plant research and development fund of 240,000 DM East.
2. First samples produced have been given to Professor Dieckmann of the Halle University Pediatrics Clinic for testing. Results have allegedly been successful.
3. Bacteriologists (Koepfel and Ullrich) and chemists (Dr. Zimmermann and his assistant) are cooperating in the development of dextran and dextran infusion solutions.
4. Large scale production is planned. Blueprints are available which show that the entire old building 2/ will be cleared for dextran production; two additional stories for this building are projected. It is not yet known whether the Dessau plant will initiate commercial production of dextran, but blueprint data indicate that facilities are planned to supply larger quantities than needed by East Germany.

CLASSIFICATION

SECRET

STATE	/x	NAVY	/x	NSRB															
ARMY	/x	AIR	/x	FBI															

25X1

